UBS Group
CLYM

UBS Group’s Climb Bio CLYM Stock Holding History

UBS Group’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.4M Buy
3,404,866
+3,318,921
+3,862% +$34.3M 0.01% 1863
2026
Q1 		$589K Buy
85,945
+14,622
+21% +$84.4K ﹤0.01% 5969
2025
Q4 		$285K Sell
71,323
-334,081
-82% -$802K ﹤0.01% 6387
2025
Q3 		$815K Buy
405,404
+22,922
+6% +$42.6K ﹤0.01% 5728
2025
Q2 		$474K Buy
382,482
+257
+0.1% +$320 ﹤0.01% 6055
2025
Q1 		$466K Sell
382,225
-33,130
-8% -$53.7K ﹤0.01% 5905
2024
Q4 		$748K Buy
415,355
+399,108
+2,457% +$1.44M ﹤0.01% 5541
2024
Q3 		$82.7K Buy
16,247
+14,029
+633% +$99.2K ﹤0.01% 6484
2024
Q2 		$15.8K Sell
2,218
-3,707
-63% -$24.7K ﹤0.01% 7458
2024
Q1 		$16.2K Buy
+5,925
New +$16.3K ﹤0.01% 7013
2023
Q4 		– Sell
-89
Closed -$234 – 10009
2023
Q3 		$234 Buy
+89
New +$243 ﹤0.01% 8667
2022
Q3 		– Sell
-2,282
Closed -$7K – 11047
2022
Q2 		$7K Buy
2,282
+666
+41% +$3.15K ﹤0.01% 8548
2022
Q1 		$14K Sell
1,616
-2,822
-64% -$26.3K ﹤0.01% 7970
2021
Q4 		$47K Sell
4,438
-9,435
-68% -$141K ﹤0.01% 6969
2021
Q3 		$249K Buy
+13,873
New +$287K ﹤0.01% 5169

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

UBS Group's CLYM Position: Q2 2026 in Review

UBS Group increased its Climb Bio (CLYM) stake by 3,862% in Q2 2026, buying an estimated $34.3M and bringing the position to 3,404,866 shares worth $44.4M. The position accounts for 0.01% of the portfolio, ranked #1863.

UBS Group first reported a position in CLYM in Q3 2021 and has held it in 15 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • UBS Group held 3,404,866 shares of Climb Bio worth $44.4M as of Q2 2026.
  • UBS Group bought 3,318,921 Climb Bio shares in Q2 2026, an estimated $34.3M.
  • Climb Bio made up 0.01% of UBS Group's portfolio in Q2 2026, its #1863 holding.
  • UBS Group first reported a position in Climb Bio in Q3 2021 and has held it in 15 quarters since.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.